Authors
Mackenzie Andrews is the CCO of Nanodropper.
Michelessi is an investigator at the Glaucoma Research Unit of the IRCCS G. B. Bietti Foundation for Study and Research in Ophthalmology in Rome, Italy.
Dr. Kraff has no financial interest in any of the products mentioned in this article. He is a clinical investigator for VISX. His presentation was given
at a VISX symposium during the American Academy
of Ophthalmology annual meeting.
e:mddesmet1@mac.com
De Smet is director of MIOS in Lausanne, Switzerland (www.retina-uveitis.eu), and medical director of Preceyes Medical Robotics (www.preceyes.nl) in Eindhoven, The Netherlands.
Mura is chief of the Retina Division at King Khaled Eye Specialist Hospital in Riyadh, Saudi Arabia, and an associate professor of ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine in Baltimore, Maryland.
McDonald is clinical professor of ophthalmology at both NYU Langone Medical Center, New York, New York and Tulane University Health Sciences Center, New Orleans, Louisiana, and in practice with OCLI Vision, Oceanside, New York. McDonald is a consultant for Johnson & Johnson Vision and ORCA Surgical.
Dr. Abelson, a clinical associate professor at Harvard Medical School, Boston.
Michels is a vitreoretinal disease specialist at Retina Care Specialists in Palm Beach Gardens, FL.
Mark P. Breazzano, MD, FACS, is Associate Professor and Vitreoretinal Fellowship Director at the Flaum Eye Institute at the University of Rochester in Rochester, New York.
Dr. Packer, is co-editor of Cataract Corner. He is assistant clinical professor of ophthalmology at Oregon Health & Science University, Portland and is in private practice in Eugene with Drs. Fine, Hoffman & Packer.